(CercleFinance.com) – Eli Lilly announced this weekend the results of a phase 2 study aimed at evaluating tirzepatide in adults with metabolic steatohepatitis (MASH) with stage 2 or 3 fibrosis.
Results showed that 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg of tirzepatide, respectively, achieved freedom from MASH without worsening fibrosis, compared to 13.2 % of participants on placebo.
The data was presented at the European Association for the Study of the Liver (EASL) 2024 Congress and published in the New England Journal of Medicine.
Regarding secondary endpoints, 59.1%, 53.3% and 54.2% of participants taking 5 mg, 10 mg and 15 mg respectively showed improvement in fibrosis without worsening of MASH, compared to 32 .8% under placebo.
Lilly is in discussions with regulatory authorities for next steps for tirzepatide in the treatment of MASH.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
